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OBJECTIVE — To compare whether depressive symptoms are more strongly related to sub-
sequent or prior glycemic control in type 2 diabetes and to test whether patient characteristics
modify these longitudinal associations.
RESEARCH DESIGN AND METHODS — On two occasions separated by 6 months,
depressive symptoms and glycemic control were assessed in 253 adults with type 2 diabetes.
Regressionanalysesexamineddepressivesymptomsasbothapredictorandoutcomeofglycemic
control and tested whether medication regimen (e.g., insulin versus oral drugs) was an effect
modiﬁer before and after adjusting for baseline levels of the outcome being predicted.
RESULTS — Depressive symptom severity predicted poor glycemic control 6 months later
(P  0.018) but not after baseline glycemic control was taken into account (P  0.361).
Although baseline glycemic control did not generally predict depressive symptoms 6 months
later (P  0.558), it signiﬁcantly interacted with regimen (P  0.008). Speciﬁcally, glycemic
controlpredicteddepressivesymptomsamongpatientsprescribedinsulin(0.31,P0.002)
but not among those prescribed oral medication alone ( 0.10, P  0.210). Classifying
depression dichotomously produced similar but weaker ﬁndings.
CONCLUSIONS — Depressive symptoms do not necessarily lead to worsened glycemic
control. In contrast, insulin-treated patients in poor glycemic control are at moderate risk for
worsening of depressive symptoms. These patients should be carefully monitored to determine
whether depression treatment should be initiated or intensiﬁed.
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L
ike type 2 diabetes, depression is a
major public health concern, affect-
ing 20 million Americans yearly
(1). Approximately 30% of individuals
with diabetes exhibit elevated depressive
symptoms, and about one-third of these
individuals meet psychiatric criteria for
depression (2).
Although epidemiological data (3,4)
suggest that depression may increase the
risk for diabetes onset, the nature and di-
rectionalityoftheassociationbetweende-
pressive symptoms and subsequent
diabetes course remain unclear. This is
because cross-sectional studies generally
indicate modest contemporaneous asso-
ciations between depression and both
glycemic control and complication rate
but cannot speak to directionality. Some
depression trials (5) suggest that mood
improvement is associated with glycemic
improvement, whereas other trials (6–8)
do not support this conclusion. Most di-
abetes treatment trials overlook depres-
sion assessment or include insufﬁcient
numbers of depressed patients to permit
subgroup analyses. With these excep-
tions, longitudinal studies relating type 2
diabetes course to temporal variation in
depressivesymptomsarerare.Severalun-
derlying mechanisms seem plausible. On
one hand, poor diabetes control is prob-
ably stressful enough to induce or worsen
depressive symptoms. In the other tem-
poral direction, depression may worsen
glycemic control through physiological
channelssuchascatecholaminicandnor-
adrenergic mechanisms and/or behavior-
ally by disrupting patients’ medical
adherence and self-care routines (9).
While naturalistic studies obviously
cannot prove causality, certain longitudi-
nal designs can test for “temporal prior-
ity,” in which one variable predicts future
values of a second variable, which in turn
does not predict future values of the ﬁrst.
The objective of the current study was to
clarify the temporal priority of the possi-
ble longitudinal associations between
type 2 diabetes control and depression by
testing whether depressive symptoms are
more strongly related to subsequent than
to prior glycemic control.
A second issue in the literature is that
depression, whether conceptualized as a
syndromal entity or symptom contin-
uum, has at best explained only a modest
portion (5%) of variance in diabetes
outcomes (3). However, certain patient
characteristicsmightmodifythiseffect.In
particular, recent preliminary studies
(10,11) suggest that depression has a
more potent role among patients who are
prescribed insulin. For example, perhaps
the need for insulin represents a psycho-
logical threat related to injection perfor-
mance anxiety, needle phobia, fear of
hypoglycemia, concerns about how oth-
ers will react to injections, and worries
about diabetes severity and progression
(12). Additionally, insulin regimen tasks
(e.g., glucose monitoring, dosage adjust-
ment) may be easily disrupted by depres-
sive symptoms such as apathy and
impaired task initiation. Therefore, the
current study also aimed to build upon
existing work by testing whether insulin
use strengthens any longitudinal associa-
tions between depression and glycemic
control.
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METHODS— Potential participants
were identiﬁed using the administrative
and clinical databases of a large Midwest-
ern urban health care system. Eligible pa-
tients had type 2 diabetes as indicated by
atleastoneofthefollowing:1)atleastone
hospitalization with a diabetes-related
ICD-9 code (250.x, 357.2, 362.0, or
366.41), 2) at least two outpatient visits
with a diabetes-related ICD-9 code, or 3)
atleastoneprescriptionforaglucosecon-
trol medication or monitoring supplies,
beingbetween18and80yearsofage,and
being able to complete self-report instru-
ments. Type 1 diabetes was further ruled
out through medical record review and
telephone screening by research staff.
Following an institutional review
board–approved protocol, eligible pa-
tientsweremailedastudyinvitationletter
followed by a recruitment telephone call
from research staff for further screening
and enrollment scheduling. After in-
formed consent, participants attended re-
search appointments at baseline and 6
months later for assessment of depressive
symptoms, glycemic control, and other
variables.
The presence of probable depressive
disorder was assessed with the Patient
Health Questionnaire-9 (PHQ-9), upon
which respondents indicated “how often,
over the last two weeks, were you both-
ered by any of the following problems?”
for each of nine depressive symptoms in-
cluded in the DSM-IV criteria for depres-
sive episodes paired with a four-point
scale ranging from “not at all” to “nearly
every day.” The PHQ-9 is 88% sensitive
and 88% speciﬁc for interview-detected
major depression in medical patients
(13). Participants were classiﬁed as either
depressed or not using the established
cutoffofPHQ-9total10.Glycemiccon-
trol (A1C) was measured with the DCA
2000 (GMI, Ramsey, MN), which ana-
lyzes capillary blood samples through a
monoclonal antibody method. Comorbid
medical illness was assessed by abstract-
ing electronic medical records using a
checklist of 13 common medical illnesses
used in prior primary care studies
(14,15), and the presence of diabetes
complicationswasmeasuredusingastan-
dard self-report checklist of visual, car-
diovascular, kidney, genitourinary, and
other common diabetes complications
taken from the validated Diabetes Care
Proﬁle (16). Participants classiﬁed them-
selvesusingU.S.Censusracial/ethniccat-
egories. Socioeconomic status (SES) was
assessedusingtheU.S.CensusBureauIn-
dex of Socioeconomic Status (17) ad-
justed for current regional Consumer
Price Index.
Data analysis
Data were analyzed using STATA 10.1 soft-
ware (StataCorp, College Station, TX). De-
scriptive analyses were conducted to
characterize the sample and examine the
data for violation of statistical assumptions.
Nonnormal distributions were rank con-
verted for analysis. Relationships between
glycemic control and depressive symptoms
were analyzed using ordinary least-squares
regressionforthepredictionof6-monthde-
pressive symptom severity and glycemic
control and logistic regression for the pre-
diction of 6-month elevation in depressive
symptoms. Main effects were evaluated
prior to including interaction terms, which
were computed as the product of regimen
(0  oral hypoglycemic alone, 1  on in-
sulin) and the other baseline predictor of
interest(i.e.,eitherdepressionorglycemia).
Comparisons were made between coefﬁ-
cients estimated before and after adjusting
models for baseline values of the 6-month
outcome being predicted.
RESULTS
Enrollment
Of828eligiblepatientssolicited,271(33%)
consented to the study and 13% dropped
outbeforethemonth-6follow-up.Attrition
was signiﬁcantly more likely among those
who were aged 60 years (P  0.032) or
African American (P  0.024) but not sig-
niﬁcantly related to socioeconomic status,
illness duration, diabetes complications,
medical comorbidity, or any primary study
variable (glycemic control, depressive
symptoms, and regimen type). The ﬁnal
sample(n253)wasdemographicallyand
medically heterogenous (Table 1). That is,
halfwerefemalesubjects,54%wereAfrican
American, age ranged from 27 to 88 years,
40%wereprescribedinsulin(almostalways
in addition to an oral hypoglycemic agent),
diabetesdurationrangedfrom1to60years,
and21%hadatleasttwosigniﬁcantcomor-
bid medical conditions.
Prediction of month-6 glycemic
control by baseline depression
First, month-6 glycemic control was re-
gressed upon baseline depressive symp-
toms, diabetes regimen type, and the
depression  regimen interaction term.
Results (Table 2) indicated that depres-
sive symptoms were prospectively associ-
ated with poor glycemic control (P 
0.018). However, this effect was no
longersigniﬁcantwhenthemodelwasad-
justed for baseline glycemic control (P 
0.361). The interaction effect did not
reach statistical signiﬁcance in either the
unadjustedmodel(0.795)ortheadjusted
model (P  0.251).
Prediction of month-6 depressive
symptoms by baseline glycemic
control
Next, we regressed month-6 depressive
symptoms upon baseline glycemia, reg-
imen, and the regimen  glycemia in-
teraction. Glycemia did not predict
Table 1—Demographic and clinical characteristics by regimen
Pooled sample
(n  253)
On oral
hypoglycemics
alone (n  153)
On insulin
(n  100) P
Age 57.3  8.3 57.8 56.6 0.246
Female 50 51.3 46.1 0.415
African American 55 49.7 64.1 0.023
Socioeconomic status index* 65.0  17.5 64.1  18.0 66.3  16.7 0.349
Diabetes duration (years) 10.9  8.2 9.0  7.0 13.8  9.1 0.001
Diabetes complications† 0.7  0.8 0.6  0.8 0.8  0.9 0.157
Two or more comorbid medical
conditions‡ 20 19.1 23.8 0.371
A1C at baseline (%) 7.57  1.61 7.37  1.54 7.89  1.67 0.015
Depressive symptom severity
(baseline PHQ-9 total) 5.5  4.7 5.0  4.1 6.2  5.4 0.060
Data are means  SD or percent. *U.S. Census Bureau Index of Socioeconomic Status adjusted for inﬂation
and regional Consumer Price Index. †Coded as 0, 1, or 2. ‡Coded from count of the following illnesses:
asthma, chronic obstructive lung disease, congestive heart failure, osteoarthritis, rheumatoid arthritis, ar-
thritis associated with lupus (SLE) or scleroderma, peripheral vascular disease, cirrhosis, chronic hepatitis,
coronary artery disease, thyroid disease, Addison’s disease, and Cushing’s syndrome.
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0.558). However, there was a signiﬁcant
regimen  glycemia interaction effect
(P  0.006) that persisted (P  0.020)
whenthemodelwasadjustedforbaseline
depressive symptoms. Regimen-stratiﬁed
follow-up regression analysis and exami-
nation of regression plots (Fig. 1) indi-
cated that hyperglycemia was positively
associated with subsequent depressive
symptoms among patients who were pre-
scribed insulin (0.31, P  0.002,
indicating “moderate” effect magnitude)
but not among those on oral hypoglyce-
mic medication alone ( 0.10, P 
0.210).
Examination of depression as a
binary indicator
UsingaPHQ-9cutoffof10toclassifypar-
ticipants as having probable depression
or not at baseline and month 6, we rean-
alyzedthedatawithdepressivesymptoms
categorized as present versus absent. Al-
thoughthegeneralpatternofﬁndingswas
similar, the effect magnitudes were some-
whatlesspronouncedandnotstatistically
signiﬁcant in all cases. As above, baseline
depression predicted month-6 glycemic
control in unadjusted (0.14, P 
0.026) but not adjusted analyses (
0.01,P0.903).Alsoasabove,therewas
a signiﬁcant glycemia  regimen interac-
tion effect on month-6 depression (odds
ratio 1.01 [95% CI 1.01–1.03], P 
0.042). However, unlike above, the inter-
action effect did not remain signiﬁcant
(1.00 [0.99–1.02], P  0.616) when the
model was adjusted for the baseline pres-
ence of depression.
Consideration of other potential
confounders
As can be seen in Table 1, insulin use was
associated with diabetes duration and
with being African American. By adjust-
ing for regimen type, we assumed that we
also indirectly adjusted for this potential
confound. Indeed, regression models
were adjusted for diabetes duration and
minority status; the pattern and signiﬁ-
cance of ﬁndings was similar to unad-
justed models. Because another study
(18)suggeststhattheassociationbetween
depression and A1C may vary by sex, we
tested both prospective interactions be-
tween sex and depressive symptoms.
However, sex did not interact with base-
line glycemic control in the prediction of
month-6 depressive symptoms (P 
0.946), nor did sex interact with baseline
depressive symptoms in the prediction of
month-6 glycemic control (P  0.727).
CONCLUSIONS— Resultsindicated
that among type 2 diabetic patients pre-
scribed insulin, poor glycemic control
predicts worsened depressive symptoms
6 months later, even after adjusting for
concurrent depressive symptoms. This
doesnotoccuramongpatientswhoareon
oral medication alone, suggesting that ei-
therinsulinuseitself(ormorelikelysome
property of insulin-treated diabetes) may
exacerbate the impact of glycemic control
upon mood symptoms. In sum, depres-
sive symptoms seem to be more linked
with hyperglycemia among insulin-
treated patients.
Although depressive symptoms in
turn predict future glycemic control, this
appearstobeovershadowedbytheeffects
of current glycemic control, indicating
that depression level does not have a pro-
spective glycemic effect beyond that ex-
plained by the stability of glycemia itself.
In other words, if depression has a pro-
spectiveanddurableeffectuponglycemic
control, this will be extraordinarily difﬁ-
cult to observe within the context of
chronic hyperglycemia.
The directional relationship between
glycemia and change in depressive symp-
toms was more pronounced among pa-
tients prescribed insulin than among
those on oral antihyperglycemic medi-
cines alone. This builds upon existing
preliminary data indicating that glycemic
control (19) and quality of life (20) are
only associated with depression among
insulin users. Moreover, we have else-
where argued that as blood glucose be-
comes more ﬂuctuating and elevated in
both type 1 and type 2 diabetes, it be-
comes more strongly related to psycho-
logical factors in general (11,21). This
patterncouldbeduetoregimencomplex-
ity and burden in terms of multiple daily
injections, regimen-related psychological
distress, and other psychological impacts
of requiring insulin (9,12). Patients may
ascribe signiﬁcant negative meaning to
theconceptofrequiringinjections,which
might increase the inﬂuence of depressed
mood upon outcomes, particularly qual-
ity of life. Finally, exogenous insulin may
have some directly depressogenic effect
on brain function, although this has not
been previously reported.
Alternatively, the apparent “regimen
speciﬁcity” of the observed temporal ef-
fects may simply be reﬂective of diabetes
severity, insofar as insulin therapy often
marks advanced diabetes. Perhaps psy-
chiatricvulnerabilityincreasesasdiabetes
advances,ahypothesisthatwouldrequire
long-termobservationtoverify.Ouranal-
ysis of potential confounds, however,
helps rule out the possibilities that the
ﬁndingsareexplainedbyillnessduration,
diabetes complications, or other medical
conditions that might be expected among
Table 2—Results of regression analyses of depressive symptoms and glycemic control
Outcome variable Predictor variables
Adjusted for
confounders
only*
Adjusted for
confounders and
baseline of
outcome being
predicted
† P † P
Month 6 glycemic
control
Baseline glycemic
control
— — 0.78 0.001
Baseline depressive
symptoms
0.15 0.018 0.04 0.361
Regimen 0.10 0.121 0.02 0.559
Depressive symptoms 
regimen
0.02 0.795 0.10 0.251
Month 6 depressive
symptoms
Baseline depressive
symptoms
— — 0.69 0.001
Baseline glycemic
control
0.07 0.258 0.03 0.558
Regimen 0.01 0.990 0.04 0.386
Glycemic control 
regimen
0.42 0.006 0.27 0.020
*Adjusted for race/ethnicity and diabetes duration. †Standardized regression coefﬁcient, with main effects
estimated simultaneously and prior to including interaction term in model.
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to require insulin treatment. Although a
prior report (18) suggests that sex may
modify the association between depres-
sionandA1C,wewereunabletoreplicate
this effect.
One of the most important study lim-
itationsisthattherearemultipleplausible
explanations for this result, many of
which cannot be addressed within this
study. First, both chronic hyperglycemia
and subsequent depressive symptoms
couldbecausedbyathirdfactorthatthey
happen to share. Examples are low levels
ofphysicalactivity,functionalrestrictions
due to diabetes or another medical condi-
tion, medical nonadherence, inadequate
treatmentsecondarytopoorappointment
attendance, and the exacerbation of an-
other medical condition. Underlying bio-
logical mechanisms have also been
suggested, such that both depression and
severe diabetes may be associated with
neurohormonal abnormalities such as el-
evated cortisol and catecholamines (22).
Additional study limitations should be
considered. The ﬁndings should be gen-
eralized with caution because, although
the sample was demographically diverse,
enrollment occurred within a single
healthsystemandonlyone-thirdofsolici-
tants actually participated, which may
have biased toward the selection of more
motivated individuals. The measure and
its cutoffs used to classify probable de-
pression were originally validated against
psychiatric interviews; however, we did
not verify depression presence by inter-
view, and therefore there may have been
some psychiatric misclassiﬁcation in the
limitedbinarycomparisonsthatwemade.
The observed associations might be ex-
plained by the dose of insulin required,
thesubjectiveburdenofusinginsulin,the
personal meaning of requiring insulin for
diabetes control, or other unmeasured
factors. Our ethical obligation to inter-
vene with suicidal participants may have
altered associations by reducing depres-
sion levels. Finally, although the design
was longitudinal, it was nonexperimental
and thus cannot clearly determine
whether glycemia plays a causal role in
the observed association.
In closing, the ﬁndings indicate that
under naturalistic circumstances, depres-
sive symptoms are more likely to be an
effect than a cause of poor glycemic con-
trol. Second, this relationship between
glycemia and subsequent depressive
symptoms occurs only among patients
who are prescribed insulin. Potential
mechanisms should be carefully studied.
Theseincludethepotentialdepressogenic
effects of poor glycemic control and the
potential existence of a common factor
thatmightexplainpooroutcomesinboth
depression and diabetes, whether it is bi-
ological, psychological, and/or related to
health care delivery. Clinicians who pro-
vidediabetescaremightbeespeciallyvig-
ilant in terms of depression screening and
managementfordiabeticpatientswhoare
prescribed insulin, inviting patients to
discuss the potential impact of insulin on
their lifestyle and mental health.
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